Rafael José Vieira MD , Luís Filipe Azevedo MD PhD , Ana Margarida Pereira MD , Diogo Nogueira-Leite PhD , Francisco Nuno Rocha Gonçalves PhD , Desirée E. Larenas-Linnemann MD , Alvaro A. Cruz MD, PhD , Bilun Gemicioglu MD, PhD , Boleslaw Samolinski MD, PhD , Leticia de las Vecillas MD, PhD , Mattia Giovannini MD , Maria João Cunha MD , Jorge Rodrigues MD, PhD , Violeta Kvedariene MD, PhD , Ludger Klimek MD, PhD , Oliver Pfaar MD, PhD , Torsten Zuberbier MD, PhD , João A. Fonseca MD, PhD , Jean Bousquet MD, PhD , Bernardo Sousa-Pinto MD, PhD
{"title":"Impact of Allergic Rhinitis Control on Work Productivity and Costs: A Real-World Data MASK-air Study","authors":"Rafael José Vieira MD , Luís Filipe Azevedo MD PhD , Ana Margarida Pereira MD , Diogo Nogueira-Leite PhD , Francisco Nuno Rocha Gonçalves PhD , Desirée E. Larenas-Linnemann MD , Alvaro A. Cruz MD, PhD , Bilun Gemicioglu MD, PhD , Boleslaw Samolinski MD, PhD , Leticia de las Vecillas MD, PhD , Mattia Giovannini MD , Maria João Cunha MD , Jorge Rodrigues MD, PhD , Violeta Kvedariene MD, PhD , Ludger Klimek MD, PhD , Oliver Pfaar MD, PhD , Torsten Zuberbier MD, PhD , João A. Fonseca MD, PhD , Jean Bousquet MD, PhD , Bernardo Sousa-Pinto MD, PhD","doi":"10.1016/j.jaip.2024.07.026","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Allergic rhinitis (AR) has a substantial socioeconomic impact associated with impaired work productivity.</div></div><div><h3>Objective</h3><div>To study the impact of AR on work productivity and estimate the corresponding indirect costs for 40 countries.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study using direct patient data from the MASK-air app on users with self-reported AR. We used the Work Productivity and Activity Impairment Questionnaire: Allergy Specific to measure the impact of AR on work productivity (presenteeism and absenteeism). Weekly indirect costs were estimated per country for each level of rhinitis control. Patients with and without asthma were considered.</div></div><div><h3>Results</h3><div>We assessed data from 677 weeks (364 patients), 280 of which were reported by patients with asthma. Regarding presenteeism, the median impact of AR in weeks of poor disease control was 60.7% (percentiles 25–75 [P25–P75] 24.9%–74.2%), whereas partial and good disease control were, respectively, associated with an impact of 25.0% (P25–P75 12.1%–42.4%) and 4.4% (P25–P75 0.8%–12.9%). In poorly controlled weeks, presenteeism was associated with indirect costs ranging from 65.7 US$ purchase power parities (PPPs) (P25–P75 29.2–143.2) in Brazil to 693.6 US$ PPP (P25–P75 405.2–1,094.9) in Iceland. Median absenteeism per week was of 0% for all levels of rhinitis control. Patients with AR + asthma showed higher overall work impairment than patients with AR alone, particularly in poorly controlled weeks (median work impairment in AR alone 39.1% [P25–P75 12.5%–71.9%]; median work impairment in AR + asthma 68.4% [P25–P75 54.6%–80.2%]).</div></div><div><h3>Conclusions</h3><div>Poor AR control was associated with decreased work productivity and increased indirect costs, particularly in patients with AR + asthma. The estimates from this study underpin the economic burden of AR.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"12 11","pages":"Pages 3107-3115.e13"},"PeriodicalIF":8.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213219824007761","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Allergic rhinitis (AR) has a substantial socioeconomic impact associated with impaired work productivity.
Objective
To study the impact of AR on work productivity and estimate the corresponding indirect costs for 40 countries.
Methods
We conducted a cross-sectional study using direct patient data from the MASK-air app on users with self-reported AR. We used the Work Productivity and Activity Impairment Questionnaire: Allergy Specific to measure the impact of AR on work productivity (presenteeism and absenteeism). Weekly indirect costs were estimated per country for each level of rhinitis control. Patients with and without asthma were considered.
Results
We assessed data from 677 weeks (364 patients), 280 of which were reported by patients with asthma. Regarding presenteeism, the median impact of AR in weeks of poor disease control was 60.7% (percentiles 25–75 [P25–P75] 24.9%–74.2%), whereas partial and good disease control were, respectively, associated with an impact of 25.0% (P25–P75 12.1%–42.4%) and 4.4% (P25–P75 0.8%–12.9%). In poorly controlled weeks, presenteeism was associated with indirect costs ranging from 65.7 US$ purchase power parities (PPPs) (P25–P75 29.2–143.2) in Brazil to 693.6 US$ PPP (P25–P75 405.2–1,094.9) in Iceland. Median absenteeism per week was of 0% for all levels of rhinitis control. Patients with AR + asthma showed higher overall work impairment than patients with AR alone, particularly in poorly controlled weeks (median work impairment in AR alone 39.1% [P25–P75 12.5%–71.9%]; median work impairment in AR + asthma 68.4% [P25–P75 54.6%–80.2%]).
Conclusions
Poor AR control was associated with decreased work productivity and increased indirect costs, particularly in patients with AR + asthma. The estimates from this study underpin the economic burden of AR.
期刊介绍:
JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases.
This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders.
The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.